Company news
PharmaTher Holdings Ltd news in 2025
PharmaTher Holdings Ltd's news releases, calls and decks from 2025, newest first.
PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise
December 2, 2025
PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program
November 17, 2025
PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale
October 17, 2025
PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease
October 16, 2025
PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings
October 15, 2025
PharmaTher Provides Update on Ketamine Program for LID-Parkinson's Disease
October 8, 2025
PharmaTher Provides Corporate Update on Ketamine Development and Commercial Strategy
October 2, 2025
PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments
October 1, 2025
PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine (KETARx(TM)), Aligned with FDA's CNPV National Priority Initiative
August 27, 2025
PharmaTher Provides Corporate Update Following FDA Approval of Ketamine (KETARx™)
August 26, 2025
PharmaTher Founder and CEO Issues Letter to Shareholders Following the FDA Approval of Ketamine (KETARx(TM))
August 14, 2025
PharmaTher Founder and CEO Issues Letter to Shareholders following the FDA Approval of Ketamine (KETARx™)
August 14, 2025
PharmaTher Announces FDA Approval of Ketamine (KETARx(TM))
August 11, 2025
PharmaTher Announces FDA Approval of Ketamine (KETARx™)
August 11, 2025
PharmaTher Announces Path to Ketamine Commercialization with No Planned Financing, Confirms FDA Approval Goal Date of August 9th, 2025 for Ketamine
July 2, 2025
PharmaTher Secures Key US Patent for Ketamine in Amyotrophic Lateral Sclerosis (ALS), Bolstering its Orphan Drug Designated Program and Targeting a Billion Dollar Market
June 24, 2025
PharmaTher Applauds FDA's New Commissioner’s National Priority Voucher (CNPV) Program, Citing Potential to Accelerate its Ketamine Programs for Mental Health, Pain, and Neurological Disorders, and National Security Applications
June 18, 2025
PharmaTher Announces FDA Extends Review Period for Ketamine; New Approval Goal Date August 9, 2025
May 16, 2025
PharmaTher Unveils KetaVault™: A First-of-Its-Kind Portal to Accelerate Ketamine Research and Commercialization
May 14, 2025
PharmaTher Receives US FDA Approval Goal Date for Ketamine
March 11, 2025
PharmaTher Provides Complete Response Amendment for US FDA New Drug Application for Ketamine
March 3, 2025